PAVmed Inc.
PAVmed Inc. PAVM Peers
See (PAVM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PAVM | $0.63 | -2.96% | 10.89M | 1.26 | $0.50 | N/A |
| ABT | $135.58 | +0.58% | 235.89B | 17.61 | $7.70 | +1.69% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $106.66 | +0.58% | 157.80B | 77.85 | $1.37 | N/A |
| SYK | $394.77 | +0.14% | 150.87B | 53.28 | $7.41 | +0.83% |
| MDT | $86.97 | +0.61% | 111.54B | 26.52 | $3.28 | +3.23% |
| EW | $78.02 | +0.03% | 45.77B | 32.24 | $2.42 | N/A |
| DXCM | $86.96 | +1.73% | 34.10B | 65.38 | $1.33 | N/A |
| STE | $252.62 | +0.41% | 24.82B | 41.01 | $6.16 | +0.89% |
| PODD | $325.84 | +0.34% | 22.93B | 56.47 | $5.77 | N/A |
Stock Comparison
PAVM vs ABT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ABT has a market cap of 235.89B. Regarding current trading prices, PAVM is priced at $0.63, while ABT trades at $135.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ABT's P/E ratio is 17.61. In terms of profitability, PAVM's ROE is +1.58%, compared to ABT's ROE of +0.24%. Regarding short-term risk, PAVM is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BSX-PA Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, PAVM is priced at $0.63, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PAVM's ROE is +1.58%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, PAVM is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BSX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BSX has a market cap of 157.80B. Regarding current trading prices, PAVM is priced at $0.63, while BSX trades at $106.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BSX's P/E ratio is 77.85. In terms of profitability, PAVM's ROE is +1.58%, compared to BSX's ROE of +0.10%. Regarding short-term risk, PAVM is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SYK Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SYK has a market cap of 150.87B. Regarding current trading prices, PAVM is priced at $0.63, while SYK trades at $394.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SYK's P/E ratio is 53.28. In terms of profitability, PAVM's ROE is +1.58%, compared to SYK's ROE of +0.11%. Regarding short-term risk, PAVM is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs MDT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, MDT has a market cap of 111.54B. Regarding current trading prices, PAVM is priced at $0.63, while MDT trades at $86.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas MDT's P/E ratio is 26.52. In terms of profitability, PAVM's ROE is +1.58%, compared to MDT's ROE of +0.09%. Regarding short-term risk, PAVM is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs EW Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, EW has a market cap of 45.77B. Regarding current trading prices, PAVM is priced at $0.63, while EW trades at $78.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas EW's P/E ratio is 32.24. In terms of profitability, PAVM's ROE is +1.58%, compared to EW's ROE of +0.49%. Regarding short-term risk, PAVM is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs DXCM Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, DXCM has a market cap of 34.10B. Regarding current trading prices, PAVM is priced at $0.63, while DXCM trades at $86.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas DXCM's P/E ratio is 65.38. In terms of profitability, PAVM's ROE is +1.58%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, PAVM is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs STE Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, STE has a market cap of 24.82B. Regarding current trading prices, PAVM is priced at $0.63, while STE trades at $252.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas STE's P/E ratio is 41.01. In terms of profitability, PAVM's ROE is +1.58%, compared to STE's ROE of +0.09%. Regarding short-term risk, PAVM is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PODD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PODD has a market cap of 22.93B. Regarding current trading prices, PAVM is priced at $0.63, while PODD trades at $325.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PODD's P/E ratio is 56.47. In terms of profitability, PAVM's ROE is +1.58%, compared to PODD's ROE of +0.35%. Regarding short-term risk, PAVM is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PHG Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PHG has a market cap of 22.08B. Regarding current trading prices, PAVM is priced at $0.63, while PHG trades at $23.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PHG's P/E ratio is 82.31. In terms of profitability, PAVM's ROE is +1.58%, compared to PHG's ROE of +0.03%. Regarding short-term risk, PAVM is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ZBH Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ZBH has a market cap of 18.96B. Regarding current trading prices, PAVM is priced at $0.63, while ZBH trades at $95.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ZBH's P/E ratio is 21.29. In terms of profitability, PAVM's ROE is +1.58%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PAVM is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ABMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, PAVM is priced at $0.63, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PAVM's ROE is +1.58%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PAVM is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ALGN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ALGN has a market cap of 13.40B. Regarding current trading prices, PAVM is priced at $0.63, while ALGN trades at $184.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ALGN's P/E ratio is 33.61. In terms of profitability, PAVM's ROE is +1.58%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PAVM is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SNN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SNN has a market cap of 12.73B. Regarding current trading prices, PAVM is priced at $0.63, while SNN trades at $29.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SNN's P/E ratio is 30.96. In terms of profitability, PAVM's ROE is +1.58%, compared to SNN's ROE of +0.08%. Regarding short-term risk, PAVM is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SWAV Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, PAVM is priced at $0.63, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PAVM's ROE is +1.58%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PAVM is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PEN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PEN has a market cap of 10.90B. Regarding current trading prices, PAVM is priced at $0.63, while PEN trades at $281.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PEN's P/E ratio is 263.09. In terms of profitability, PAVM's ROE is +1.58%, compared to PEN's ROE of +0.04%. Regarding short-term risk, PAVM is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs GMED Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, GMED has a market cap of 8.27B. Regarding current trading prices, PAVM is priced at $0.63, while GMED trades at $61.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas GMED's P/E ratio is 45.57. In terms of profitability, PAVM's ROE is +1.58%, compared to GMED's ROE of +0.05%. Regarding short-term risk, PAVM is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BIO Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BIO has a market cap of 6.77B. Regarding current trading prices, PAVM is priced at $0.63, while BIO trades at $248.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BIO's P/E ratio is -3.24. In terms of profitability, PAVM's ROE is +1.58%, compared to BIO's ROE of -0.32%. Regarding short-term risk, PAVM is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BIO-B Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BIO-B has a market cap of 6.72B. Regarding current trading prices, PAVM is priced at $0.63, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BIO-B's P/E ratio is -3.83. In terms of profitability, PAVM's ROE is +1.58%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, PAVM is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BRKR Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BRKR has a market cap of 5.73B. Regarding current trading prices, PAVM is priced at $0.63, while BRKR trades at $37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BRKR's P/E ratio is 72.69. In terms of profitability, PAVM's ROE is +1.58%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, PAVM is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs GKOS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, GKOS has a market cap of 5.48B. Regarding current trading prices, PAVM is priced at $0.63, while GKOS trades at $95.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas GKOS's P/E ratio is -42.22. In terms of profitability, PAVM's ROE is +1.58%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, PAVM is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs NARI Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, PAVM is priced at $0.63, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas NARI's P/E ratio is -59.24. In terms of profitability, PAVM's ROE is +1.58%, compared to NARI's ROE of -0.18%. Regarding short-term risk, PAVM is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs IRTC Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, IRTC has a market cap of 4.53B. Regarding current trading prices, PAVM is priced at $0.63, while IRTC trades at $141.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas IRTC's P/E ratio is -45.30. In terms of profitability, PAVM's ROE is +1.58%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, PAVM is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs INSP Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, INSP has a market cap of 4.42B. Regarding current trading prices, PAVM is priced at $0.63, while INSP trades at $149.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas INSP's P/E ratio is 68.75. In terms of profitability, PAVM's ROE is +1.58%, compared to INSP's ROE of +0.10%. Regarding short-term risk, PAVM is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ITGR Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ITGR has a market cap of 4.24B. Regarding current trading prices, PAVM is priced at $0.63, while ITGR trades at $121.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ITGR's P/E ratio is 56.47. In terms of profitability, PAVM's ROE is +1.58%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, PAVM is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs TMDX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, TMDX has a market cap of 4.13B. Regarding current trading prices, PAVM is priced at $0.63, while TMDX trades at $122.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas TMDX's P/E ratio is 85.99. In terms of profitability, PAVM's ROE is +1.58%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, PAVM is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AXNX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, PAVM is priced at $0.63, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PAVM's ROE is +1.58%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PAVM is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PRCT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PRCT has a market cap of 3.28B. Regarding current trading prices, PAVM is priced at $0.63, while PRCT trades at $59.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PRCT's P/E ratio is -35.08. In terms of profitability, PAVM's ROE is +1.58%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, PAVM is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs LIVN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, LIVN has a market cap of 2.40B. Regarding current trading prices, PAVM is priced at $0.63, while LIVN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas LIVN's P/E ratio is -10.80. In terms of profitability, PAVM's ROE is +1.58%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, PAVM is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs NUVA Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, PAVM is priced at $0.63, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PAVM's ROE is +1.58%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PAVM is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ATEC Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ATEC has a market cap of 1.90B. Regarding current trading prices, PAVM is priced at $0.63, while ATEC trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ATEC's P/E ratio is -11.43. In terms of profitability, PAVM's ROE is +1.58%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, PAVM is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CNMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CNMD has a market cap of 1.86B. Regarding current trading prices, PAVM is priced at $0.63, while CNMD trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CNMD's P/E ratio is 15.82. In terms of profitability, PAVM's ROE is +1.58%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, PAVM is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs UFPT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, UFPT has a market cap of 1.86B. Regarding current trading prices, PAVM is priced at $0.63, while UFPT trades at $241.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas UFPT's P/E ratio is 29.64. In terms of profitability, PAVM's ROE is +1.58%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, PAVM is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs TNDM Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, TNDM has a market cap of 1.51B. Regarding current trading prices, PAVM is priced at $0.63, while TNDM trades at $22.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas TNDM's P/E ratio is -8.15. In terms of profitability, PAVM's ROE is +1.58%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, PAVM is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs HSKA Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, PAVM is priced at $0.63, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PAVM's ROE is +1.58%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PAVM is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AORT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AORT has a market cap of 1.27B. Regarding current trading prices, PAVM is priced at $0.63, while AORT trades at $29.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AORT's P/E ratio is -58.25. In terms of profitability, PAVM's ROE is +1.58%, compared to AORT's ROE of -0.07%. Regarding short-term risk, PAVM is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AHCO Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AHCO has a market cap of 1.21B. Regarding current trading prices, PAVM is priced at $0.63, while AHCO trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AHCO's P/E ratio is 15.50. In terms of profitability, PAVM's ROE is +1.58%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, PAVM is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SILK Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, PAVM is priced at $0.63, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SILK's P/E ratio is -18.96. In terms of profitability, PAVM's ROE is +1.58%, compared to SILK's ROE of -0.37%. Regarding short-term risk, PAVM is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs FNA Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, PAVM is priced at $0.63, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas FNA's P/E ratio is -19.83. In terms of profitability, PAVM's ROE is +1.58%, compared to FNA's ROE of -0.36%. Regarding short-term risk, PAVM is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ESTA Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ESTA has a market cap of 1.06B. Regarding current trading prices, PAVM is priced at $0.63, while ESTA trades at $36.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ESTA's P/E ratio is -11.80. In terms of profitability, PAVM's ROE is +1.58%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, PAVM is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs IART Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, IART has a market cap of 1.05B. Regarding current trading prices, PAVM is priced at $0.63, while IART trades at $13.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas IART's P/E ratio is -35.66. In terms of profitability, PAVM's ROE is +1.58%, compared to IART's ROE of -0.03%. Regarding short-term risk, PAVM is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs INMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, INMD has a market cap of 1.01B. Regarding current trading prices, PAVM is priced at $0.63, while INMD trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas INMD's P/E ratio is 6.52. In terms of profitability, PAVM's ROE is +1.58%, compared to INMD's ROE of +0.25%. Regarding short-term risk, PAVM is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CSII Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, PAVM is priced at $0.63, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CSII's P/E ratio is -20.83. In terms of profitability, PAVM's ROE is +1.58%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PAVM is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CRY Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, PAVM is priced at $0.63, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CRY's P/E ratio is 425.71. In terms of profitability, PAVM's ROE is +1.58%, compared to CRY's ROE of -0.07%. Regarding short-term risk, PAVM is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SIBN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, PAVM is priced at $0.63, while SIBN trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SIBN's P/E ratio is -22.60. In terms of profitability, PAVM's ROE is +1.58%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, PAVM is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs IRMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, IRMD has a market cap of 689.29M. Regarding current trading prices, PAVM is priced at $0.63, while IRMD trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas IRMD's P/E ratio is 34.97. In terms of profitability, PAVM's ROE is +1.58%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PAVM is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs RXST Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, RXST has a market cap of 663.20M. Regarding current trading prices, PAVM is priced at $0.63, while RXST trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas RXST's P/E ratio is -24.73. In terms of profitability, PAVM's ROE is +1.58%, compared to RXST's ROE of -0.10%. Regarding short-term risk, PAVM is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CBLL Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CBLL has a market cap of 644.43M. Regarding current trading prices, PAVM is priced at $0.63, while CBLL trades at $17.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CBLL's P/E ratio is -14.26. In terms of profitability, PAVM's ROE is +1.58%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, PAVM is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BFLY-WT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BFLY-WT has a market cap of 615.47M. Regarding current trading prices, PAVM is priced at $0.63, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, PAVM's ROE is +1.58%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, PAVM is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AVNS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AVNS has a market cap of 600.71M. Regarding current trading prices, PAVM is priced at $0.63, while AVNS trades at $12.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AVNS's P/E ratio is -1.57. In terms of profitability, PAVM's ROE is +1.58%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, PAVM is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs APEN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, PAVM is priced at $0.63, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas APEN's P/E ratio is -9.43. In terms of profitability, PAVM's ROE is +1.58%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PAVM is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BFLY Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BFLY has a market cap of 574.95M. Regarding current trading prices, PAVM is priced at $0.63, while BFLY trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BFLY's P/E ratio is -7.75. In terms of profitability, PAVM's ROE is +1.58%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, PAVM is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs KIDS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, KIDS has a market cap of 568.45M. Regarding current trading prices, PAVM is priced at $0.63, while KIDS trades at $22.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas KIDS's P/E ratio is -13.04. In terms of profitability, PAVM's ROE is +1.58%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, PAVM is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs NPCE Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, NPCE has a market cap of 557.57M. Regarding current trading prices, PAVM is priced at $0.63, while NPCE trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas NPCE's P/E ratio is -20.73. In terms of profitability, PAVM's ROE is +1.58%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, PAVM is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AXGN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AXGN has a market cap of 535.60M. Regarding current trading prices, PAVM is priced at $0.63, while AXGN trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AXGN's P/E ratio is -73.50. In terms of profitability, PAVM's ROE is +1.58%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, PAVM is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs OFIX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, OFIX has a market cap of 472.52M. Regarding current trading prices, PAVM is priced at $0.63, while OFIX trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas OFIX's P/E ratio is -3.26. In terms of profitability, PAVM's ROE is +1.58%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, PAVM is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BVS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BVS has a market cap of 459.86M. Regarding current trading prices, PAVM is priced at $0.63, while BVS trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BVS's P/E ratio is -14.44. In terms of profitability, PAVM's ROE is +1.58%, compared to BVS's ROE of -0.21%. Regarding short-term risk, PAVM is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs TMCI Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, TMCI has a market cap of 423.35M. Regarding current trading prices, PAVM is priced at $0.63, while TMCI trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas TMCI's P/E ratio is -7.92. In terms of profitability, PAVM's ROE is +1.58%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, PAVM is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SRDX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SRDX has a market cap of 421.54M. Regarding current trading prices, PAVM is priced at $0.63, while SRDX trades at $29.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SRDX's P/E ratio is -21.06. In terms of profitability, PAVM's ROE is +1.58%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, PAVM is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CLPT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CLPT has a market cap of 370.84M. Regarding current trading prices, PAVM is priced at $0.63, while CLPT trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CLPT's P/E ratio is -17.26. In terms of profitability, PAVM's ROE is +1.58%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, PAVM is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SENS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SENS has a market cap of 352.92M. Regarding current trading prices, PAVM is priced at $0.63, while SENS trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SENS's P/E ratio is -4.90. In terms of profitability, PAVM's ROE is +1.58%, compared to SENS's ROE of -7.46%. Regarding short-term risk, PAVM is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs NNOX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, NNOX has a market cap of 349.42M. Regarding current trading prices, PAVM is priced at $0.63, while NNOX trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas NNOX's P/E ratio is -6.02. In terms of profitability, PAVM's ROE is +1.58%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, PAVM is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs OM Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, OM has a market cap of 347.00M. Regarding current trading prices, PAVM is priced at $0.63, while OM trades at $19.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas OM's P/E ratio is -0.68. In terms of profitability, PAVM's ROE is +1.58%, compared to OM's ROE of -1.45%. Regarding short-term risk, PAVM is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CTKB Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CTKB has a market cap of 340.71M. Regarding current trading prices, PAVM is priced at $0.63, while CTKB trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CTKB's P/E ratio is -29.89. In terms of profitability, PAVM's ROE is +1.58%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, PAVM is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs VREX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, VREX has a market cap of 332.42M. Regarding current trading prices, PAVM is priced at $0.63, while VREX trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas VREX's P/E ratio is -7.78. In terms of profitability, PAVM's ROE is +1.58%, compared to VREX's ROE of -0.08%. Regarding short-term risk, PAVM is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SMLR Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SMLR has a market cap of 312.27M. Regarding current trading prices, PAVM is priced at $0.63, while SMLR trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SMLR's P/E ratio is 6.34. In terms of profitability, PAVM's ROE is +1.58%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, PAVM is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PACB Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PACB has a market cap of 306.09M. Regarding current trading prices, PAVM is priced at $0.63, while PACB trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PACB's P/E ratio is -0.37. In terms of profitability, PAVM's ROE is +1.58%, compared to PACB's ROE of -1.25%. Regarding short-term risk, PAVM is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs VMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, VMD has a market cap of 266.79M. Regarding current trading prices, PAVM is priced at $0.63, while VMD trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas VMD's P/E ratio is 22.50. In terms of profitability, PAVM's ROE is +1.58%, compared to VMD's ROE of +0.10%. Regarding short-term risk, PAVM is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CERS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CERS has a market cap of 252.33M. Regarding current trading prices, PAVM is priced at $0.63, while CERS trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CERS's P/E ratio is -13.20. In terms of profitability, PAVM's ROE is +1.58%, compared to CERS's ROE of -0.35%. Regarding short-term risk, PAVM is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ZIMV Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ZIMV has a market cap of 244.31M. Regarding current trading prices, PAVM is priced at $0.63, while ZIMV trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ZIMV's P/E ratio is -9.72. In terms of profitability, PAVM's ROE is +1.58%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, PAVM is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs MXCT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, MXCT has a market cap of 242.41M. Regarding current trading prices, PAVM is priced at $0.63, while MXCT trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas MXCT's P/E ratio is -5.70. In terms of profitability, PAVM's ROE is +1.58%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, PAVM is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs TCMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, TCMD has a market cap of 241.78M. Regarding current trading prices, PAVM is priced at $0.63, while TCMD trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas TCMD's P/E ratio is 15.76. In terms of profitability, PAVM's ROE is +1.58%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, PAVM is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs NVRO Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, PAVM is priced at $0.63, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PAVM's ROE is +1.58%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PAVM is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs EYES Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, PAVM is priced at $0.63, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas EYES's P/E ratio is N/A. In terms of profitability, PAVM's ROE is +1.58%, compared to EYES's ROE of -0.26%. Regarding short-term risk, PAVM is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CATX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CATX has a market cap of 204.13M. Regarding current trading prices, PAVM is priced at $0.63, while CATX trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CATX's P/E ratio is -2.24. In terms of profitability, PAVM's ROE is +1.58%, compared to CATX's ROE of -0.27%. Regarding short-term risk, PAVM is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BWAY Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BWAY has a market cap of 200.99M. Regarding current trading prices, PAVM is priced at $0.63, while BWAY trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BWAY's P/E ratio is 48.41. In terms of profitability, PAVM's ROE is +1.58%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, PAVM is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs TLSI Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, TLSI has a market cap of 196.01M. Regarding current trading prices, PAVM is priced at $0.63, while TLSI trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas TLSI's P/E ratio is -3.95. In terms of profitability, PAVM's ROE is +1.58%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, PAVM is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs QTRX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, QTRX has a market cap of 189.10M. Regarding current trading prices, PAVM is priced at $0.63, while QTRX trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas QTRX's P/E ratio is -3.93. In terms of profitability, PAVM's ROE is +1.58%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, PAVM is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ELMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ELMD has a market cap of 184.28M. Regarding current trading prices, PAVM is priced at $0.63, while ELMD trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ELMD's P/E ratio is 27.82. In terms of profitability, PAVM's ROE is +1.58%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, PAVM is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs BDMD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, BDMD has a market cap of 180.44M. Regarding current trading prices, PAVM is priced at $0.63, while BDMD trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas BDMD's P/E ratio is 14.54. In terms of profitability, PAVM's ROE is +1.58%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, PAVM is more volatile compared to BDMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs CVRX Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, CVRX has a market cap of 178.60M. Regarding current trading prices, PAVM is priced at $0.63, while CVRX trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas CVRX's P/E ratio is -3.20. In terms of profitability, PAVM's ROE is +1.58%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, PAVM is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs RCEL Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, RCEL has a market cap of 178.17M. Regarding current trading prices, PAVM is priced at $0.63, while RCEL trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas RCEL's P/E ratio is -3.08. In terms of profitability, PAVM's ROE is +1.58%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, PAVM is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ANIK Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ANIK has a market cap of 174.39M. Regarding current trading prices, PAVM is priced at $0.63, while ANIK trades at $12.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ANIK's P/E ratio is -16.21. In terms of profitability, PAVM's ROE is +1.58%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, PAVM is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs MASS Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, MASS has a market cap of 171.06M. Regarding current trading prices, PAVM is priced at $0.63, while MASS trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas MASS's P/E ratio is -2.15. In terms of profitability, PAVM's ROE is +1.58%, compared to MASS's ROE of -0.13%. Regarding short-term risk, PAVM is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs SGHT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, SGHT has a market cap of 169.07M. Regarding current trading prices, PAVM is priced at $0.63, while SGHT trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas SGHT's P/E ratio is -3.34. In terms of profitability, PAVM's ROE is +1.58%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, PAVM is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs LNSR Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, LNSR has a market cap of 166.27M. Regarding current trading prices, PAVM is priced at $0.63, while LNSR trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas LNSR's P/E ratio is -2.90. In terms of profitability, PAVM's ROE is +1.58%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, PAVM is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs INGN Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, INGN has a market cap of 164.82M. Regarding current trading prices, PAVM is priced at $0.63, while INGN trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas INGN's P/E ratio is -5.33. In terms of profitability, PAVM's ROE is +1.58%, compared to INGN's ROE of -0.15%. Regarding short-term risk, PAVM is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs PROF Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, PROF has a market cap of 149.96M. Regarding current trading prices, PAVM is priced at $0.63, while PROF trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas PROF's P/E ratio is -4.12. In terms of profitability, PAVM's ROE is +1.58%, compared to PROF's ROE of -0.70%. Regarding short-term risk, PAVM is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs RPID Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, RPID has a market cap of 145.08M. Regarding current trading prices, PAVM is priced at $0.63, while RPID trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas RPID's P/E ratio is -3.21. In terms of profitability, PAVM's ROE is +1.58%, compared to RPID's ROE of -0.56%. Regarding short-term risk, PAVM is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs AVR Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, AVR has a market cap of 143.40M. Regarding current trading prices, PAVM is priced at $0.63, while AVR trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas AVR's P/E ratio is -2.02. In terms of profitability, PAVM's ROE is +1.58%, compared to AVR's ROE of -2.92%. Regarding short-term risk, PAVM is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs LUCD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, LUCD has a market cap of 136.32M. Regarding current trading prices, PAVM is priced at $0.63, while LUCD trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas LUCD's P/E ratio is -1.20. In terms of profitability, PAVM's ROE is +1.58%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, PAVM is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs LUNG Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, LUNG has a market cap of 134.46M. Regarding current trading prices, PAVM is priced at $0.63, while LUNG trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas LUNG's P/E ratio is -2.32. In terms of profitability, PAVM's ROE is +1.58%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, PAVM is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs MYO Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, MYO has a market cap of 121.97M. Regarding current trading prices, PAVM is priced at $0.63, while MYO trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas MYO's P/E ratio is -24.21. In terms of profitability, PAVM's ROE is +1.58%, compared to MYO's ROE of -0.36%. Regarding short-term risk, PAVM is more volatile compared to MYO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ICAD Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ICAD has a market cap of 109.23M. Regarding current trading prices, PAVM is priced at $0.63, while ICAD trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ICAD's P/E ratio is -18.95. In terms of profitability, PAVM's ROE is +1.58%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, PAVM is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs XTNT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, XTNT has a market cap of 99.62M. Regarding current trading prices, PAVM is priced at $0.63, while XTNT trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas XTNT's P/E ratio is -7.94. In terms of profitability, PAVM's ROE is +1.58%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, PAVM is more volatile compared to XTNT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs HJLI Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, PAVM is priced at $0.63, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas HJLI's P/E ratio is N/A. In terms of profitability, PAVM's ROE is +1.58%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, PAVM is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs MGRM Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, MGRM has a market cap of 96.00M. Regarding current trading prices, PAVM is priced at $0.63, while MGRM trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas MGRM's P/E ratio is -5.27. In terms of profitability, PAVM's ROE is +1.58%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, PAVM is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs ASXC Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, PAVM is priced at $0.63, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas ASXC's P/E ratio is -1.12. In terms of profitability, PAVM's ROE is +1.58%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, PAVM is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.
PAVM vs OWLT Comparison
PAVM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVM stands at 10.89M. In comparison, OWLT has a market cap of 86.09M. Regarding current trading prices, PAVM is priced at $0.63, while OWLT trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVM currently has a P/E ratio of 1.26, whereas OWLT's P/E ratio is -3.24. In terms of profitability, PAVM's ROE is +1.58%, compared to OWLT's ROE of +1.37%. Regarding short-term risk, PAVM is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVM.